Sarepta Continues To Show Results In DMD, But Is It Enough?
This article was originally published in The Pink Sheet Daily
The biotech announced positive results from a small Phase IIb study, but investors are wary and it’s still unclear whether regulators will consider the data to be clear cut enough for approval.
You may also be interested in...
The New Jersey-based biotech has not lost its optimism after a setback in Europe for its lead product and is showing growth in other areas.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.